Inactive Instrument

Aravive, Inc.

Equities

ARAV

US03890D1081

Biotechnology & Medical Research

Aravive, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 11, 2023 at 01:37 am IST

Aravive, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was USD 1.49 million compared to USD 1.09 million a year ago. Net loss was USD 49.96 million compared to USD 13.06 million a year ago.

Basic loss per share from continuing operations was USD 0.66 compared to USD 0.62 a year ago.

Latest news about Aravive, Inc.

Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index	31/01	CI
Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index	26/01	CI
Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	19/01	MT
Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market	18/01	MT
Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer	18/01	CI
Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer	18/01	CI
Aravive, Inc. Announces Board and Committee Resignations	18/01	CI
North American Morning Briefing : Stocks Seen -2-	15/11	DJ
Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
North American Morning Briefing : Nasdaq Futures -2-	24/23/24	DJ
North American Morning Briefing : Nvidia Results -2-	23/23/23	DJ
Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	22/23/22	MT
Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/23/22	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	17/23/17	DJ
North American Morning Briefing : Stocks Seen -2-	04/23/04	DJ
Sector Update: Health Care Stocks Slipping Late Thursday	04/23/04	MT
Sector Update: Health Care	04/23/04	MT
Top Midday Decliners	04/23/04	MT
EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	03/23/03	MT
HC Wainwright Downgrades Aravive to Neutral From Buy	03/23/03	MT
William Blair Downgrades Aravive to Market Perform From Outperform	03/23/03	MT
BTIG Downgrades Aravive to Neutral From Buy	03/23/03	MT
Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	03/23/03	CI
BTIG Adjusts Price Target on Aravive to $9 From $12, Maintains Buy Rating	10/23/10	MT
Aravive, Inc.(NasdaqGS:ARAV) added to Russell 3000E Growth Index	23/23/23	CI

Chart Aravive, Inc.

Duration

Period

More charts

Company Profile

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.01%	11TCr
BIONTECH SE	-3.07%	2.47TCr
ARGENX SE	-0.64%	2.2TCr
GENMAB A/S	-4.55%	1.93TCr
BEIGENE, LTD.	-6.90%	1.76TCr
WUXI APPTEC CO., LTD.	-39.36%	1.73TCr
NEUROCRINE BIOSCIENCES, INC.	+5.82%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+33.05%	1.21TCr

Bio Therapeutic Drugs